Kenvue
KVUE
$19.03
-1.04%
Kenvue Inc. is the world's largest pure-play consumer health company, generating over $15 billion in annual revenue from a portfolio of iconic brands including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. As a former Johnson & Johnson consumer segment that spun off in May 2023, Kenvue holds a dominant position in categories like self-care, essential health, and skin health, leveraging its scale and brand equity to compete globally. The current investor narrative centers on the pending acquisition by Kimberly-Clark, announced in November 2025 and expected to close in the second half of 2026, which has created uncertainty around the stock's standalone prospects while also providing a potential floor via the deal terms. Additionally, the company is navigating post-IPO challenges including litigation, competitive pressures, and a recent earnings beat that has sparked cautious optimism about its turnaround trajectory.…
KVUE
Kenvue
$19.03
Related headlines
Investment Opinion: Should I buy KVUE Today?
Based on the analysis, KVUE is rated a Hold. The consensus recommendation is 'Hold' with an average target price of $19.83, implying only 3.4% upside. The thesis is that the stock is fairly valued with limited upside, but the acquisition provides a floor. Investors should wait for more clarity on the deal and operational improvements.
Sign up to view all
KVUE 12-Month Price Forecast
The AI assessment is neutral, reflecting balanced risks and rewards. The stock offers a defensive profile with a decent dividend, but growth is limited. The acquisition is the key swing factor; if it closes, the stock could re-rate higher, but if it fails, downside is significant. Upgrades to bullish would require evidence of accelerating growth or successful acquisition synergies, while downgrades would occur if the deal collapses or dividend is cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kenvue's 12-month outlook, with a consensus price target around $19.67 and implied upside of +3.4% versus the current price.
Average Target
$19.67
0 analysts
Implied Upside
+3.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $23
Analyst target range
Analyst coverage is moderate with 12 analysts, and the consensus recommendation is 'Hold' with a mean rating of 2.79 (where 1 is strong buy and 5 is sell). The average target price is $19.83, implying a modest 3.4% upside from the current price of $19.18. The distribution shows a neutral stance, with no strong bullish or bearish bias, reflecting uncertainty around the acquisition and the company's standalone growth prospects. The low target is $18.00, which is 6.2% below the current price, while the high target is $23.00, representing 19.9% upside. The wide spread of $5.00 between low and high indicates significant uncertainty about the stock's future, likely due to the pending acquisition and litigation risks. Recent ratings actions have been predominantly neutral or hold, with Jefferies downgrading from Buy to Hold in January 2026, suggesting analysts are cautious about near-term catalysts. The consensus implies that the stock is fairly valued, with limited upside absent a successful acquisition or operational turnaround.
Bulls vs Bears: KVUE Investment Factors
Kenvue presents a mixed picture: strong margins, a defensive profile, and a potential acquisition floor are countered by low growth, high payout, and litigation risks. The bull case rests on margin expansion and the acquisition providing a floor, while the bear case highlights limited standalone growth and dividend sustainability. Currently, the bear case has slightly stronger evidence given the modest growth and high payout ratio, but the acquisition could tilt the balance. The most critical tension is whether the acquisition closes successfully and at what terms, as this will determine the stock's near-term trajectory.
Bullish
- Q1 2026 earnings beat: Kenvue reported Q1 2026 revenue of $3.909B, up 4.5% YoY, and EPS of $0.25, beating expectations. This beat triggered a stock rise and analyst upgrades, signaling a potential turnaround after post-IPO struggles.
- Strong gross margin expansion: Gross margin improved to 58.9% in Q1 2026 from 56.5% in Q4 2025, reflecting better cost management and pricing power. This margin expansion supports profitability and cash flow generation.
- Attractive forward valuation: Forward PE of 15.4x is at a discount to the trailing PE of 22.3x and the industry average of 22x, implying the market expects significant earnings growth. The PEG ratio of 0.52 suggests the stock is undervalued relative to its growth prospects.
- Defensive consumer staples profile: With a beta of 0.43, Kenvue offers low market correlation, making it a defensive play. Revenue growth of 4.5% YoY in a mature market provides stability, and the 4.8% dividend yield adds income appeal.
Bearish
- Limited standalone growth: Revenue growth has been modest, with Q1 2026 up only 4.5% YoY, and the company operates in mature categories. This low growth profile limits upside potential for the stock as a standalone entity.
- High payout ratio and dividend risk: The payout ratio is 107.5%, meaning the company is paying out more than its earnings in dividends. This is unsustainable and could lead to a dividend cut, especially if earnings decline.
- Litigation and regulatory overhang: Kenvue faces product litigation, including talc-related claims, which could result in significant costs. Recent news highlights litigation as a headwind, and any adverse ruling could impact earnings and stock price.
- Analyst downgrades and neutral sentiment: Analyst consensus is 'Hold' with a mean rating of 2.79, and Jefferies downgraded from Buy to Hold in January 2026. This reflects cautious sentiment and limited near-term catalysts.
KVUE Technical Analysis
Kenvue's stock is in a recovery phase after a prolonged downtrend, with the 1-year price change at -10.5% but the 3-month change at +9.0%, indicating a shift in momentum. The current price of $19.18 sits at 61% of the 52-week range (low $14.02, high $21.96), suggesting the stock has rebounded from its lows but still has upside to prior highs. This positioning implies a potential value opportunity if the recovery continues, though it remains below the 52-week high, reflecting lingering bearish sentiment from the post-IPO decline.
Beta
0.43
0.43x market volatility
Max Drawdown
-38.2%
Largest decline past year
52-Week Range
$14-$22
Price range past year
Annual Return
-10.8%
Cumulative gain past year
| Period | KVUE Return | S&P 500 |
|---|---|---|
| 1m | -2.3% | +2.4% |
| 3m | +8.9% | +4.7% |
| 6m | +2.6% | +11.7% |
| 1y | -10.8% | +21.3% |
| ytd | +9.9% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KVUE Fundamental Analysis
Revenue growth has been modest but steady, with the most recent quarter (Q1 2026) showing revenue of $3.909 billion, up 4.5% year-over-year, and a sequential improvement from $3.78 billion in Q4 2025. The multi-quarter trend shows revenue fluctuating between $3.66 billion and $4.00 billion over the past two years, indicating a stable but low-growth profile typical of consumer staples. Segment data reveals Self Care as the largest driver at $1.699 billion, followed by Essential Health at $1.151 billion and Skin Health and Beauty at $1.059 billion, with no major segment dragging growth significantly. The company's ability to maintain positive growth in a mature market supports its defensive investment case, though the pace is unexciting.
Quarterly Revenue
$3.9B
2026-03
Revenue YoY Growth
+4.5%
YoY Comparison
Gross Margin
58.9%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KVUE Overvalued?
Given Kenvue's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 22.3x, while the forward PE is 15.4x, implying the market expects earnings growth of roughly 45% over the next year, which is aggressive given the company's historical growth. This gap suggests the market is pricing in a significant earnings recovery, possibly driven by the acquisition or cost synergies. Compared to the industry average PE of 22x (from valuation data), Kenvue's trailing PE is roughly in line, but the forward PE is at a discount, indicating the market is not fully crediting the growth potential. Historically, the stock's PE has ranged from 17x to 148x over the past three years, with the current trailing PE near the lower end of that range, suggesting the stock is not overvalued relative to its own history, though the forward PE implies optimism.
PE
22.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high payout ratio of 107.5%, indicating dividends exceed earnings, which could force a cut if earnings falter. The debt-to-equity ratio of 0.79 is moderate, but interest expenses of $95M in Q1 2026 pressure net income. Free cash flow of $1.823B TTM provides some cushion, but the current ratio of 0.96 suggests potential liquidity concerns. Revenue concentration in mature categories limits growth, and any margin compression could hurt profitability.